Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market
Cuprina Holdings (Nasdaq: CUPR) has made two significant announcements in the bio-therapeutics space. First, the company appointed Dr. Ronald A. Sherman, a pioneer in medical maggot therapy, as Medical and Scientific Director effective September 2025. Second, Cuprina secured a license for Dr. Sherman's 2004 FDA clearance to market Lucilia sericata Medical Maggots™ in the United States.
Dr. Sherman will lead clinical initiatives, develop training frameworks, and provide regulatory guidance. Cuprina is also pursuing FDA clearance for another maggot species, Lucilia cuprina, with potential approval expected within 90 business days. The U.S. market for maggot debridement therapy was valued at $13.9 million in 2024 and is projected to reach $24.8 million by 2030, growing at a 10.1% CAGR.
Cuprina Holdings (Nasdaq: CUPR) ha annunciato due importanti novità nel settore delle bio-terapie. In primo luogo, la società ha nominato Dr. Ronald A. Sherman, pioniere nella terapia medica con larve, come Direttore Medico e Scientifico a partire da settembre 2025. In secondo luogo, Cuprina ha ottenuto la licenza per la approvazione FDA del 2004 del Dr. Sherman per commercializzare le Lucilia sericata Medical Maggots™ negli Stati Uniti.
Il Dr. Sherman guiderà le iniziative cliniche, svilupperà programmi di formazione e fornirà supporto regolatorio. Cuprina sta inoltre perseguendo l’approvazione FDA per un’altra specie di larve, Lucilia cuprina, con una possibile approvazione prevista entro 90 giorni lavorativi. Il mercato statunitense per la terapia di debridement con larve è stato valutato 13,9 milioni di dollari nel 2024 e si prevede che raggiungerà 24,8 milioni di dollari entro il 2030, con una crescita annua composta del 10,1%.
Cuprina Holdings (Nasdaq: CUPR) ha realizado dos anuncios importantes en el ámbito de las bio-terapias. Primero, la compañía nombró a Dr. Ronald A. Sherman, pionero en la terapia médica con larvas, como Director Médico y Científico a partir de septiembre de 2025. Segundo, Cuprina obtuvo la licencia para la aprobación FDA de 2004 del Dr. Sherman para comercializar Lucilia sericata Medical Maggots™ en Estados Unidos.
El Dr. Sherman liderará iniciativas clínicas, desarrollará programas de capacitación y proporcionará asesoría regulatoria. Cuprina también está buscando la aprobación de la FDA para otra especie de larvas, Lucilia cuprina, con una posible aprobación esperada dentro de 90 días hábiles. El mercado estadounidense para la terapia de desbridamiento con larvas fue valorado en 13,9 millones de dólares en 2024 y se proyecta que alcance 24,8 millones de dólares para 2030, creciendo a una tasa compuesta anual del 10,1%.
Cuprina Holdings (나스닥: CUPR)가 바이오 치료 분야에서 두 가지 중요한 발표를 했습니다. 첫째, 이 회사는 의료 구더기 치료의 선구자인 Dr. Ronald A. Sherman을 2025년 9월부터 의료 및 과학 이사로 임명했습니다. 둘째, Cuprina는 Dr. Sherman의 2004년 FDA 승인을 기반으로 미국 내 Lucilia sericata Medical Maggots™ 판매 라이선스를 확보했습니다.
Dr. Sherman은 임상 프로젝트를 주도하고 교육 체계를 개발하며 규제 지침을 제공할 예정입니다. Cuprina는 또한 다른 구더기 종인 Lucilia cuprina에 대한 FDA 승인을 추진 중이며, 90 영업일 내에 승인이 예상됩니다. 미국의 구더기 제거 치료 시장은 2024년에 1,390만 달러 규모였으며, 2030년까지 2,480만 달러에 이를 것으로 예상되며, 연평균 성장률은 10.1%입니다.
Cuprina Holdings (Nasdaq : CUPR) a fait deux annonces importantes dans le domaine des bio-thérapeutiques. Premièrement, la société a nommé Dr Ronald A. Sherman, pionnier de la thérapie médicale par larves, en tant que Directeur Médical et Scientifique à compter de septembre 2025. Deuxièmement, Cuprina a obtenu une licence pour l'autorisation FDA de 2004 du Dr Sherman pour commercialiser les Lucilia sericata Medical Maggots™ aux États-Unis.
Le Dr Sherman dirigera les initiatives cliniques, développera des programmes de formation et fournira des conseils réglementaires. Cuprina poursuit également une autorisation FDA pour une autre espèce de larves, Lucilia cuprina, avec une approbation potentielle attendue sous 90 jours ouvrables. Le marché américain de la thérapie par débridement aux larves était évalué à 13,9 millions de dollars en 2024 et devrait atteindre 24,8 millions de dollars d'ici 2030, avec un taux de croissance annuel composé de 10,1%.
Cuprina Holdings (Nasdaq: CUPR) hat zwei bedeutende Ankündigungen im Bereich der Bio-Therapeutika gemacht. Erstens ernannte das Unternehmen Dr. Ronald A. Sherman, einen Pionier der medizinischen Maden-Therapie, zum Medizinischen und Wissenschaftlichen Direktor mit Wirkung ab September 2025. Zweitens sicherte sich Cuprina eine Lizenz für Dr. Shermans FDA-Freigabe von 2004 zur Vermarktung der Lucilia sericata Medical Maggots™ in den USA.
Dr. Sherman wird klinische Initiativen leiten, Schulungsprogramme entwickeln und regulatorische Beratung bieten. Cuprina strebt zudem eine FDA-Freigabe für eine weitere Madenart, Lucilia cuprina, an, mit einer erwarteten Genehmigung innerhalb von 90 Werktagen. Der US-Markt für Maden-Debridement-Therapie hatte 2024 einen Wert von 13,9 Millionen US-Dollar und wird voraussichtlich bis 2030 auf 24,8 Millionen US-Dollar anwachsen, bei einer jährlichen Wachstumsrate von 10,1%.
- Secured FDA-approved medical maggot license for immediate U.S. market entry
- Potential second FDA clearance for Lucilia cuprina species within 90 business days
- Appointment of industry pioneer Dr. Sherman brings 30+ years of expertise
- U.S. market projected to reach $24.8M by 2030 with 10.1% CAGR
- None.
Insights
Cuprina's strategic appointment of MDT pioneer Dr. Sherman and FDA license acquisition positions them for significant US market entry and global expansion.
Cuprina's appointment of Dr. Ronald Sherman represents a significant strategic development that substantially enhances their position in the maggot debridement therapy (MDT) market. Dr. Sherman brings unparalleled credentials to Cuprina—he secured the first-ever FDA clearance for medical maggots in 2004 and has 30+ years of specialized experience in biotherapy. The licensing agreement for his FDA clearance for Lucilia sericata Medical Maggots™ provides Cuprina immediate entry into the $13.9 million US MDT market, which is projected to grow to $24.8 million by 2030 at a 10.1% CAGR.
What makes this particularly valuable is the dual-species strategy Cuprina is pursuing. The company is simultaneously seeking FDA clearance for another maggot species (Lucilia cuprina), which could be approved within 90 business days. If successful, Cuprina would hold FDA clearances for two distinct maggot species, creating significant competitive differentiation and flexibility for international regulatory submissions.
Beyond market access, Dr. Sherman will establish structured training and certification frameworks for biotherapeutics, potentially creating industry standards while accelerating clinical adoption. His expertise in regulatory navigation across Southeast Asia and MENA regions aligns perfectly with Cuprina's global expansion strategy. This appointment essentially combines immediate market access with long-term capacity building in an emerging medical treatment field with documented cost advantages over conventional wound treatments.
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025.
Cuprina also announced it has signed an agreement with Dr. Sherman licensing his 2004 FDA clearance to market Lucilia sericata Medical MaggotsTM, the first such marketing clearance in US history. This agreement gives Cuprina the right to manufacture, sell, use and distribute these maggots and associated dressings for use in maggot debridement therapy (MDT) in the United States.
Upon joining Cuprina, Dr. Sherman’s roles and responsibilities are expected to include the following:
Clinical Leadership on Bio-Therapeutics:
- Serve as clinical and key opinion leader on maggot therapy, leech therapy, ichthyotherapy, and other company bio-therapeutic initiatives; and
- Provide mentorship, insights, and scientific guidance to Cuprina and affiliated clinicians in adopting and expanding bio-therapeutic practices.
Training, Education and Awareness:
- Co-develop, with Cuprina, a structured training and certification framework for bio-therapeutics;
- Assist in designing the syllabus and modules for education and certification; and
- Represent Cuprina as a speaker at conferences, seminars, and public events to raise awareness and advance the adoption of bio-therapeutics.
Regulatory and Clinical Trials Support:
- Provide expert guidance and counsel in navigating regulatory requirements across Southeast Asia and the MENA region; and
- Assist in designing and reviewing clinical trial protocols or supporting documentation when required by Cuprina.
“We are thrilled to join forces with Dr. Sherman,” said Cuprina chief executive David Quek. “Not only will Ron provide our company with unparalleled clinical expertise and regulatory affairs guidance for our medical maggot therapies, he will also collaborate with Cuprina to develop a structured training and certification framework for bio-therapeutics – an initiative we believe will further our goal of educating clinicians to increase their adoption rate of MDT globally.”
Mr. Quek added that Cuprina is currently updating its own FDA submission for the use of another species of medical maggots, Lucilia cuprina. Upon receiving marketing clearance – which could come within 90 business days -- Cuprina would hold two U.S. FDA clearances for individual maggot species in MDT.
This achievement, stated Mr. Quek, would give the Company the flexibility of pursuing MDT-related regulatory approval for either species in other nations.
Dr. Sherman has over 30 years experience in the field of biotherapy. After earning a BS in Entomology at UC Riverside, an MD at UCLA, and completing his Internal Medicine Residency at UC Davis in 1987, he went on to obtain a Masters in Clinical Tropical Medicine at the London School of Hygiene and completed an Infectious Diseases Fellowship at UC Irvine in 1991, during which he began his clinical studies of wound care and maggot therapy.
After continuing these studies for four years working at the Veterans Affairs Medical Center in Long Beach, CA, Dr. Sherman joined the faculty of UC Irvine, where for the next thirteen years he continued his research in maggot therapy and maggot biochemistry. In 2004, shortly after the FDA started regulating medicinal maggots as a medical device, he was granted FDA marketing clearance for the medical maggots produced in his laboratory. Dr. Sherman left UC Irvine in 2008 to devote his time to co-founding and overseeing a medical maggot laboratory (now known as Monarch Labs), supplying medical grade maggots to physicians throughout North America.
Since 2003 Dr. Sherman has served as director of the non-profit, BioTherapeutics Education & Research Foundation, whose mission is to support patient care, education, and research in maggot therapy, leech therapy, and the other biotherapeutic modalities. He has also worked as an HIV Clinic physician at the Orange County Public Health Care Agency since 1997, delivering healthcare to the county’s uninsured.
According to a June 2025 study by Research and Markets, the US market for maggot debridement therapy in 2024 was valued at
About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https://cuprina.com/.
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of the prospectus filed with the SEC and its other SEC filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com
FAQ
What is the significance of Cuprina's (CUPR) FDA license acquisition for medical maggots?
Who is Dr. Ronald Sherman and what role will he play at Cuprina (CUPR)?
What is the market size for maggot debridement therapy in the United States?
What are Cuprina's (CUPR) plans for FDA clearance of Lucilia cuprina?
How will Dr. Sherman's appointment impact Cuprina's (CUPR) bio-therapeutic initiatives?
